# Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

> **NCT01812707** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 100 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Placebo (for alirocumab)
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT01812707
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01812707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01812707, "Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01812707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*